A Waltz with Taltz – Dermatologists Report Early Adoption of Ixekizumab in Psoriasis

Download Report Overview

At just over one month post launch, one-third of dermatologists report having prescribed Eli Lilly’s IL-17 inhibitor, Taltz, according to a recent report from Spherix Global Insights.

July 26, 2016 – Cambridge, Massachusetts. At approximately six weeks after launch of Eli Lilly’s Taltz, one-third of surveyed dermatologists (n=99) report trialling the latest biologic. RealTime Dynamix™: Psoriasis is an independent report issued on a quarterly basis that provides highly granular brand insights on the psoriasis market.

Although familiarity with Taltz and the ever-present reimbursement and access environment are reported as the leading barriers to adoption, more than 95% of the survey respondents anticipate using Taltz in their practice. Current users expect their use of Taltz to more than triple in the next three months, while during the same time frame more than 20% of non-users expect to initiate trial.

While most Taltz patients are being switched from anti-TNF agents, more than a quarter of the new starts originated from Janssen’s Stelara and Novartis’ Cosentyx. Dermatologists who have started to use Taltz are four times as likely to give Taltz more favorable ratings on efficacy than Cosentyx. As familiarity with Taltz increases, the battle for preferred second line biologic will become increasingly fierce. Future projections show both IL-17’s gaining ground while projections for Stelara are flat.

Celgene’s Otezla has a mixed bag of opportunity. Dermatologists like the convenience of an oral agent and the safety profile of Otezla, but report that nearly one-third of their currently treated patients are not achieving optimal results, with many planning to discontinue Otezla at the next visit. Even with potential discontinuations, dermatologists are still projecting increased use of this drug across all severity levels.

The next survey will field in August and will continue to track the market penetration of Taltz. An in-depth patient audit planned for November will provide further insight about line of therapy progression and a detailed profile analysis for patients treated with Otezla and biologics.

To view media coverage of this release, click here.

About Spherix Global Insights
Spherix Global Insights is a newly established business intelligence and market research company. We specialize in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.

For more information contact:
Lynn Price, Immunology Franchise Head
Email: lynn.price@spherixglobalinsights.com